Allos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010
February 17 2010 - 7:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that Company
management will provide a corporate update and review of the fourth
quarter and full year 2009 results via webcast and conference call
on Monday, March 1, 2010, at 4:30 p.m. ET.
To access the live audio webcast or the subsequent archived
recording, visit the “Investors - Presentations and Events” section
of the Company’s website at www.allos.com. Alternatively, callers
may participate in the conference call by dialing 1-877-941-9205
(domestic) or 480-629-9835 (international). Participants should
reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available
approximately two hours after the completion of the call through
March 15, 2010. To access the replay, callers should dial
1-800-406-7325 (domestic) or 303-590-3030 (international) and use
passcode 4230206#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYNTM (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The fourth quarter and full year 2009
results press release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors"
section of the Company's Form 10-Q for the quarter ended September
30, 2009 and in the company's other periodic reports and filings
with the Securities and Exchange Commission. Allos is providing the
information contained in the press release and conference call as
of the date of the release and does not undertake any obligation to
update any forward-looking statements as a result of new
information, future events or otherwise. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call.
No forward-looking statement can be guaranteed and actual events
and results may differ materially from those projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics, Inc. News Articles